BREAST CANCER

Rowan T. Chlebowski, MD, PhD, professor and chief, Harbor-University of California Los Angeles Medical Center, Department of Internal Medicine, Medical Oncology/Hematology, discusses breast cancer prevention.

While targeting HER2 mutations is mainly associated with breast cancer, there could be therapeutic potential with anti-HER2 agents in non-small cell lung cancer (NSCLC).

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.

Pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, was approved by the European Commission (EC) as a neoadjuvant therapy for adult patients who have HER2-positive, locally advanced, inflammatory, or early stage breast cancer and are at high risk of recurrence.

Major disparities in compliance, follow-up, and access have been identified in the Appalachian region of the United States, according to researchers from the University of Virginia School of Medicine.

A recent combined analysis of the BOLERO-1 and -3 studies showed that PIK3CA mutations and low/no expression of PTEN linked to an extension in progression-free survival (PFS) for patients who have metastatic HER2-positive breast cancer and are treated with a combination of everolimus, trastuzumab, and paclitaxel.

Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).

Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).

Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.

An ongoing randomized trial in triple-negative breast cancer (TNBC) is evaluating the safety and efficacy of an antibody-drug conjugate that targets glycoprotein NMB (gpNMB), which is associated with reduced metastasis-free and overall survival.

Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.

CIB1 could represent a novel target for the development of targeted therapies in triple-negative breast cancer.

The National Comprehensive Cancer Network guidelines support genetic testing in individuals who are genetically predisposed to cancer.

The oral selective small molecule HER2 inhibitor ONT-380 in combination with other therapies demonstrated promising activity in previously treated patients with HER2-positive metastatic breast cancer, including those with CNS metastases.

Neoadjuvant ado-trastuzumab emtansine demonstrated promising complete pathological response in patients with hormone receptor-positive and HER2-positive early stage breast cancer

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.

Triple-Negative Breast Cancer